Cart is empty Multiple myeloma is still an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment. Immunotherapy is an attractive strategy to target myeloma cells with drug resistance. A next-generation modality that can safely and effectively strengthen immunotherapeutic effects while overcoming the characteristics of myeloma cells is needed in order to break through these obstacles.
Leave A Comment